Press Releases
Stay up to date with press releases covering announcements, company news, product launches, and business updates.
Publish your press release
INNOCOS Returns to Zurich as Longevity Forces a Reckoning Across Beauty, Wellness and Consumer Brands
EIN Presswire
The flagship summit convenes leaders to address the questions the industry can no longer avoid: proof, trust, diagnostics & the rise of the clinic as a channel.
Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
GlobeNewswire, Inc.
PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever reported PVR reduction in any...
Medical Device Contract Manufacturing Market to Grow from USD 83.77 Billion in 2025 to USD 140.84 Billion by 2030, at a CAGR of 10.9% – MarketsandMarkets™
GlobeNewswire, Inc.
Delray Beach, FL, Aug. 14, 2026 (GLOBE NEWSWIRE) -- MarketsandMarkets™ projects the global medical device contract manufacturing market will grow from USD 83.77 billion in 2025 to USD 140.84 billion by 2030, at a CAGR of 10.9% during the forecast...
CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
GlobeNewswire, Inc.
ZUG, Switzerland and BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday,...
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1
GlobeNewswire, Inc.
U.S. Food and Drug Administration accepted the New Drug Application with Priority Review for tinlarebant for the treatment of Stargardt disease type 1; Prescription Drug User Fee Act target action date of February 12, 2027 If approved, tinlarebant...
SEALSQ Expands its Quantum Highway™: Nine Interconnected Hubs Now Link La Línea, Murcia, Toulouse, Meyreuil, Grenoble, Geneva, Lausanne and the Future Swiss-based Center, and Extend the Sovereign Quantum Corridor to Chicago with EeroQ
GlobeNewswire, Inc.
Geneva, Switzerland, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The Quantum Highway physically connects every layer of the SEALQUANTUM.com Sovereign Quantum Vertical Stack, from post-quantum device manufacturing in Spain, through secure-element and ASIC...
Global Stroke Burden Keeps Rising Despite Falling Stroke Rates
EIN Presswire
New study shows prevention strategies aimed only at "high-risk" individuals are not enough to reverse the trend.
Ascom secures major framework agreement and two subsequent project awards, strengthening its long-term presence in Norway’s healthcare market
GlobeNewswire, Inc.
Baar, Switzerland, 8 September 2026 Ascom has secured one of two major framework agreements with Helse Sør-Øst (HSØ), Norway’s largest regional health authority.
UNITAR and Empower School of Health Deliver Inaugural Youth Career Accelerator in Health
UN International Training and Research Center
07 September 2026, Geneva, Switzerland - UNITAR, in partnership with Empower School of Health, delivered the inaugural edition of the Youth Career Accelerator in Health (YCAH), bringing students and early-career professionals from 16 countries to...
Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call
GlobeNewswire, Inc.
BASEL, Switzerland and LONDON and NEW YORK, Sept. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Pulmovant today announced that results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with...
Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy
GlobeNewswire, Inc.
Dosing ongoing in fully recruited dose level 2 of MP0712 Phase 1/2a study; initial safety data to be presented at North America Conference on Lung Cancer in December 2026, efficacy data expected in 2027 Emerging clinical data from lead...
Coin Cell Batteries Market to Reach USD 3.27 Billion by 2035, Driven by Wearables and Medical Devices
EIN Presswire
Asia-Pacific is the fastest-growing region, reflecting a surge in wearable technology and IoT applications.
Helsinn announces UK MHRA approval of AKYNZEO® Oral Suspension
GlobeNewswire, Inc.
Lugano, Switzerland – October 29th, 2026 – Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, today announced that the UK Medicines and Healthcare products Regulatory...
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
GlobeNewswire, Inc.
ZUG, Switzerland, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated...
ONWARD Medical to Announce First-Half 2026 Results on September 9, 2026
GlobeNewswire, Inc.
EINDHOVEN, the Netherlands, Sept. 04, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal...
Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress
GlobeNewswire, Inc.
Tokyo, Japan and Cambridge, UK, 3 September 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals Limited (“Centessa”), a wholly-owned subsidiary of Eli Lilly and Company (“Lilly”), has...
Newron Pharmaceuticals to Participate in H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire, Inc.
MILAN, Italy and MORRISTOWN, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the...
Retinal Robotics Pioneers Launch VisioSurgical Solutions (VSS) to Bring Compact Surgical Robots to Every Retina Surgeon
GlobeNewswire, Inc.
LAUSANNE, Switzerland, Oct. 29, 2026 (GLOBE NEWSWIRE) -- VisioSurgical Solutions (VSS), a Swiss medical robotics company founded by the team behind the first retinal surgery robot, today announced its launch and the start of development of a...
Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
GlobeNewswire, Inc.
ZUG, Switzerland, October 29th, 2026 -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and...
ONWARD Medical Announces First Implant in New Clinical Feasibility Study Evaluating ARC-IM System to Restore Mobility After Spinal Cord Injury
GlobeNewswire, Inc.
The EIGER study will assess the safety and preliminary effectiveness of the investigational ARC-IM® System to restore mobility after both subacute and chronic spinal cord injury ARC-IM is an implanted neuromodulation platform designed to deliver...
Sign up for:
Switzerland Health Monitor
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.